Lipid Accumulation Product Index as a Marker of Metabolic Syndrome in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis
Abstract
Background: Lipid accumulation product (LAP) index is a measure of lipid toxicity based on triglyceride and waist circumference. The aim of the current study is to explore the relationship between LAP index and metabolic syndrome (MetS) among women with polycystic ovary syndrome (PCOS) in a systematic review and meta-analysis.
Methods: Web of Science, Embase and PubMed online databases were systematically searched for studies investigating the relationship between LAP index and MetS in PCOS. Ten observational studies, including 12 populations with 2957 individuals, were identified for analysis. Mean difference and bivariate diagnostic test accuracy (DTA) meta-analyses were performed.
Results: A significant LAP index difference of 49.17 was found in women with PCOS with and without MetS (95% CI [40.57, 57.77]). By DTA meta-analysis, the pooled sensitivity and specificity of LAP index for MetS detection were 87% (I2 78%, 95% CI [80%, 92%]) and 88% (I2 78%, 95% CI [83%, 92%]), respectively, with area under the curve of 0.94 (95% CI [0.91, 0.96]).
Conclusion: The LAP index is an affordable, specific and sensitive marker for MetS and may be considered a pragmatic tool for MetS detection among patients with PCOS, particularly those with an insulin resistance endotype.
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 2,957 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.